- Document Number:
20160067256
- Appl. No:
14/855314
- Application Filed:
September 15, 2015
- نبذة مختصرة :
Methods and compounds for the treatment or prevention of oxidative damage in a mammalian subject. The treatment and/or prevention may be on inhibiting heme-induced lipid peroxidation. Also discloses are methods and compounds for treating or preventing isoprostane-mediated tissue damage.
- Claim:
1. A method for treating, preventing, or reducing oxidative damage in a mammalian subject comprising administering a therapeutically effective amount of a compound of the following formula: [chemical expression included] wherein X is independently N or C, with the C being unsubstituted or substituted with H or alkyl; R1 is independently H or alkyl; R2 is H or alkyl; R3 is H or alkyl R4 is independently H or alkyl, or forms a 6-member ring with R2 or R3 that contains C or O as ring members, the C ring members being unsubstituted or substituted with H or alkyl; or a pharmaceutically acceptable salt thereof.
- Claim:
2. The method of claim 1, wherein the therapeutically effective amount is a heme-induced lipid peroxidation inhibiting amount.
- Claim:
3. The method of claim 1, wherein the compound is selected from the group consisting of: [chemical expression included] wherein R1 is H or alkyl; R2 is H or alkyl; R3 is H or alkyl; or a pharmaceutically acceptable salts thereof.
- Claim:
4. The method of claim 1, wherein the compound is: [chemical expression included] or a pharmaceutically acceptable salts thereof.
- Claim:
5. (canceled)
- Claim:
6. A method of preventing or treating isoprostane-mediated tissue damage in a mammalian subject comprising administering a therapeutically effective amount of a compound of the following formula: [chemical expression included] wherein X is independently N or C, with the C being unsubstituted or substituted with H or alkyl; X2 is C, O, or NR5; R1 is independently H or alkyl; R2 is H or alkyl; R3 is H or alkyl R4 is independently H or alkyl, or forms a 6-member ring with R2 or R3 that contains C or O as ring members, the C ring members being unsubstituted or substituted with H or alkyl; R5 is selected from hydrogen, alkyl, C3-10 cycloalkyl, aryl, benzyl, heteroaryl, halogen, CN CF3, CO, CO-alkyl; R6 is selected from hydrogen, alkyl, C3-10 cycloalkyl, aryl, benzyl, heteroaryl, halogen, CN CF3, CO, CO-alkyl; or a pharmaceutically acceptable salt thereof.
- Claim:
7. The method of claim 6, wherein the therapeutically effective amount is an isoprostane synthesis inhibiting amount.
- Claim:
8. The method of claim 6, wherein the compound is selected from the group consisting of [chemical expression included] wherein R1 is independently H or alkyl; R2 is independently H or alkyl; R3 is H or alkyl; or a pharmaceutically acceptable salts thereof.
- Claim:
9. The method of claim 6, wherein the compound is: [chemical expression included] or a pharmaceutically acceptable salts thereof.
- Claim:
10. (canceled)
- Claim:
11. A method for inhibiting cyclooxygenase or prostaglandin H synthase enzymes, comprising administering a therapeutically effective amount of a compound of the following formula: [chemical expression included] wherein X is independently N or C, with the C being unsubstituted or substituted with H or alkyl; X2 is C, O, or NR5; R1 is independently H or alkyl; R2 is H or alkyl; R3 is H or alkyl R4 is independently H or alkyl, or forms a 6-member ring with R2 or R3 that contains C or O as ring members, the C ring members being unsubstituted or substituted with H or alkyl; R5 is selected from hydrogen, alkyl, C3-10 cycloalkyl, aryl, benzyl, heteroaryl, halogen, CN CF3, CO, CO-alkyl; R6 is selected from hydrogen, alkyl, C3-10 cycloalkyl, aryl, benzyl, heteroaryl, halogen, CN CF3, CO, CO-alkyl; or a pharmaceutically acceptable salt thereof.
- Claim:
12. The method of claim 11, wherein the compound is selected from the group consisting of [chemical expression included] wherein R1 is independently H or alkyl; R2 is independently H or alkyl; R3 is H or alkyl; or a pharmaceutically acceptable salts thereof.
- Claim:
13. The method of claim 11, wherein the compound is: [chemical expression included] or a pharmaceutically acceptable salts thereof.
- Claim:
14.-20. (canceled)
- Claim:
21. The method of claim 1, wherein the compound is selected from the group consisting of: [chemical expression included] [chemical expression included]
- Claim:
22. The method of claim 6, wherein the compound [chemical expression included] [chemical expression included]
- Claim:
23. The method of claim 11, wherein the compound [chemical expression included] [chemical expression included]
- Claim:
24. A method for treating, preventing, or reducing oxidative damage in a mammalian subject comprising administering a therapeutically effective amount of a compound of the following formula: [chemical expression included] wherein: X is N or C, with the C being unsubstituted or substituted with H or alkyl; R1 is H or alkyl; R2 is H or alkyl; R3 is H or alkyl; R4 is independently H or alkyl; X1 is [chemical expression included] wherein R is H, alkyl, cycloalkyl, aryl, or —C(O)R; and Y is CH2, NR, or O; or a pharmaceutically acceptable salt thereof.
- Claim:
25. A method of preventing or treating isoprostane-mediated tissue damage in a mammalian subject comprising administering a therapeutically effective amount of a compound of the following formula: [chemical expression included] wherein X is N or C, with the C being unsubstituted or substituted with H or alkyl; R1 is independently H or alkyl; R2 is H or alkyl; R3 is H or alkyl; R4 is independently H or alkyl; and X1 is [chemical expression included] wherein R is H, alkyl, cycloalkyl, aryl, or —C(O)R; and Y is CH2, NR, or O; or a pharmaceutically acceptable salt thereof.
- Current International Class:
61; 61; 61; 61
- الرقم المعرف:
edspap.20160067256
Processing Request
No Comments.